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Metastatic disease still lacks effective treatments, and remains the primary cause of cancermortality. Therefore, there
is a critical need to develop better strategies to inhibit metastatic cancer. The Rho family GTPase Rac is an ideal target
for anti-metastatic cancer therapy, because Rac is a key molecular switch that is activated by a myriad of cell surface
receptors to promote cancer cell migration/invasion and survival. Previously, we reported the design and development
of EHop-016, a small molecule compound, which inhibits Rac activity of metastatic cancer cells with an IC50 of 1 μM.
EHop-016 also inhibits the activity of the Rac downstream effector p21-activated kinase (PAK), lamellipodia extension,
and cell migration in metastatic cancer cells. Herein, we tested the efficacy of EHop-016 in a nude mouse model of
experimental metastasis, where EHop-016 administration at 25 mg/kg body weight (BW) significantly reduced
mammary fat pad tumor growth, metastasis, and angiogenesis. As quantified by UPLC MS/MS, EHop-016 was
detectable in the plasma of nude mice at 17 to 23 ng/ml levels at 12 h following intraperitoneal (i.p.) administration of
10 to 25 mg/kg BW EHop-016. The EHop-016 mediated inhibition of angiogenesis In Vivo was confirmed by
immunohistochemistry of excised tumors and by In Vitro tube formation assays of endothelial cells. Moreover, EHop-
016 affected cell viability by down-regulating Akt and Jun kinase activities and c-Myc and Cyclin D expression, as well
as increasing caspase 3/7 activities in metastatic cancer cells. In conclusion, EHop-016 has potential as an anticancer
compound to block cancer progression via multiple Rac-directed mechanisms.
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Cancer progression to metastasis contributes to the poor prognosis of
cancer patients due to the aggressive and invasive behavior of cancer
cells that evade the immune system and establish tumors at distant
organs. Therefore, there is a critical need to design and develop
therapeutics that can block cancer cell invasion and migration away
from the primary tumor [1,2]. The closely related members of the
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their pivotal roles in actin cytoskeleton organization, migration/
invasion and metastasis, epithelial to mesenchymal transition,
transcription, cell proliferation, cell cycle progression, apoptosis,
vesicle trafficking, angiogenesis, and cell adhesions [3–5]. Indeed,
studies from us and others have implicated hyperactive Rac1 and
Rac3 with increased survival, proliferation, and invasion of many
cancer types [6–10]. In addition to promoting cancer malignancy,
Rac and Cdc42 have also been shown to be essential for Ras and other
oncogene-mediated transformation [11,12].
Racs [1–3] are activated by a myriad of cell surface receptors that
include: integrins, G protein coupled receptors, growth factor receptors,
and cytokine receptors. These cell surface receptors regulate cancer
promoting signal cascades that have been implicated with Rac and its
direct downstream effector p21-activated kinase (PAK) activity [13].
These pathways include: phosphoinositide 3-kinase (PI3-K)/Akt/
mammalian target of Rapamycin (mTOR); signal transducer and
activator of transcription (STATs); and the mitogen activated protein
kinases (MAPKs): extracellular regulated kinase (ERK), jun kinase
(JNK), and p38 MAPK [14–18]. Activated Rac has also been shown to
affect cell proliferation via signaling to the oncogenes c-Myc and Cyclin
D [19]. Therefore, Rac GTPases play a pivotal role in regulation of
cancer malignancy, and targeting Racs appear to be a viable strategy to
impede cancer metastasis [8,15,20,21].
Unlike Ras, RhoGTPases are notmutated in disease but activated via
the deregulation of expression and/or activity of their upstream
regulators, guanine nucleotide exchange factors (GEFs) [22]. Accord-
ingly, although ~9% of melanomas were recently found to contain an
activating Racmutation [23], and the hyperactive splice variant Rac1b is
frequently overexpressed in cancer [24], a majority of the Rac proteins
in human cancer are activated due to up-regulated GEFs [21,25,26]. So
far, over 70 potential Rac GEFs are known; and many members of the
largest family of Rac GEFs, the Dbl family, have been identified as
oncogenes [22,27–29].Of the RacGEFs, T-cell invasion andmetastasis
gene product (Tiam-1), Trio, Vav (1/2/3), and PIP3-dependent Rac
exchanger (p-Rex1/2) have been implicated in the progression of
metastatic breast and other cancers [30–35]. Therefore, the binding of
GEFs to Rac and Cdc42 has been targeted as a rational strategy to
inhibit their activity; and thus, metastasis.
The Rac inhibitor NSC23766 was identified as a small molecule
compound that inhibits the interaction of Rac with the GEFs Trio
and Tiam1 [36–38]. NSC23766 has been used to demonstrate the
significance of Rac activity in cancer cell proliferation, survival,
migration, metastasis, and therapy resistance [10,39–43]. However,
the high effective concentrations (IC50 N75 μM) of NSC23766 limit
its use as a therapeutic agent [36]. Other known Rac inhibitors also
have IC50s of 10 to 50 μM [44,45]; including the recently published
Rac inhibitors AZA1, ZINC69391, and IA-116 [46,47]. At
concentrations ranging from 5 to 20 μM, AZA1 acted as a dual
inhibitor for Rac and Cdc42, and blocked prostate cancer cell
proliferation, cell migration, and reduced Cyclin D1, and PAK and
Akt activities [46]. Another compound ZINC69361, which inhibited
Rac activity with an IC50 of 61 μM and reduced lung metastasis, was
used as a lead to derive IA-116, which was selective for Rac and
inhibited the interaction between Rac and the Rac GEF p-Rex1;
albeit, at μM effective concentrations [47].
Recent studies have also shown the utility of the NSC23766
derivative AZA197, which was identified as a selective inhibitor for
the closely related Rac homolog Cdc42. AZA197, at 1 to 10 μM,inhibited the Cdc42 GEF Dbs activity, PAK and ERK activities, and
reduced Cyclin D levels, colon cancer cell proliferation, and cancer
progression in amousemodel [48]. The potency of this inhibitor is similar
to that ofML141 (CID2950007), another Cdc42 selective inhibitor with
an IC50 ~3 to 5 μM [49], that was shown to inhibit melanoma cell
migration [50]. These data demonstrate the utility of developing chemical
probes to target both Rac and Cdc42 in malignant cancer.
To improve the efficacy of NSC23766 and its derivatives, we
developed a panel of related compounds [51], and identified EHop-
016 as a Rac inhibitor that is 100 times more potent than
NSC23766, and binds to the effector domain of Rac1 with a tighter
interaction [52]. To our knowledge, EHop-016 is one of the most
potent Rac inhibitors that has been published, and is an effective tool
for probing Rac function in cell and mouse models; as has been shown
by us and others, in studies using breast cancer cell lines, leukemia,
melanoma, and T lymphocytes [50,52–54]. We reported that EHop-
016 inhibits the Rac activity of metastatic cancer cells with an IC50 of
1 μM by blocking the specific interaction of Rac with the Rac GEF
and oncogene Vav. EHop-016 also inhibits the activity of the Rac
downstream effector PAK, lamellipodia extension, and cell migration
in metastatic cancer cells at concentrations less than 10 μM, while
concentrations ≥10 μM inhibits the activity of the close Rac homolog
Cdc42, and cell viability [52,53].
The aim of this study was to test the In Vivo effects of EHop-016 in
cancer progression. We used metastatic cancer cell lines and a mouse
model of experimental metastasis to demonstrate the efficacy of EHop-
016 at reducing mammary fat pad tumor growth, metastasis, and
angiogenesis. We also found that EHop-016 inhibited cell survival and
proliferation regulators, and induced apoptosis in metastatic cancer
cells; thus, highlighting its potential as an anticancer compound.Materials and Methods
Cell Culture
The human metastatic breast cancer cell line MDA-MB-435
expressing green fluorescent protein (GFP) (kind gift of Dr. Danny
Welch, The University of Alabama at Birmingham, AL, 2009) was
cultured, as described in [55]. The prostate cancer cell line PC3 was
purchased from American Type Culture Collection (ATCC,
Manassas, VA) and was cultured in Roswell Park Memorial Institute
(RPMI) Medium supplemented with 10% heat inactivated fetal
bovine serum (FBS) at 37°C in 5% CO2. Primary Human Umbilical
Vein Endothelial Cells (HUVECs) were purchased from ATCC and
were cultured at 37°C in 5% CO2 using the endothelial cell growth
kit-BBE media (Vascular cell Basal media + added supplements) from
ATCC, as per manufacturer instructions.
EHop-016 Synthesis
Ehop-016 was synthesized as previously described by us in [52].
Stock solutions were made in 10% dH2O and 90% DMSO.
Immunohistochemistry
Tumor specimens were embedded in optimal cutting temperature
(OCT) medium. Sections (5 μm) were fixed for two minutes each in
acetone, chloroform:acetone, and acetone at −20°C. Washed slides
were incubated in blocking buffer (3% horse serum, 3% goat serum)
and then with anti-CD31 (1:50 dilution; Abcam, Cambridge, MA)
overnight in a humid chamber at 4°C, followed by incubation with
Alexa Fluor 594 goat anti-rabbit (1:2000; Life Technologies,
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sections were counterstained with 49-6-diamidino-2-phenylindole
(DAPI) (1:5,000; Santa Cruz Biotechnology, Santa Cruz, CA) and
mounted. Digital photographs were obtained using a Nikon Eclipse TS
100 Invertedmicroscope (Nikon,Melville, NY) with the NIS-Elements F
3.0 software and a Zeiss AxiocamMRc (Carl Zeiss, Gottingen, Germany).
Capillary Tube Formation Assay
Capillary tube formation was analyzed using 1:5 Matrigel matrix
(Corning, Tewksbury, MA) in ice-cold buffer (10 mM of Tris Base
0.7% NaCl, pH 8), solidified by incubation at 37°C for ~1.5 h. A
total of 40,000 HUVECs/well, pre-treated with vehicle (0.1%
DMSO) or 8 μM of Ehop-016 for 24 h, were seeded into Matrigel
pre-coated (200 μl/well) 48-well plates. Fresh vehicle or 8 μM of
Ehop-016 was added to the corresponding treatments during the
assay. Tube formation was monitored following a 3 h incubation at
37°C and 5% CO2.
Rac Activity Assay
HUVECs or PC3 cells were treated with vehicle or 8 μMEhop-016.
After 24 h, cells were lysed and total protein was quantified using the
Precision Red protein assay kit (Cytoskeleton, Inc., Denver, CO).
Active Rac was pulled down using beads coupled to GST–p21-activated
kinase (PAK)-Cdc42/Rac interactive binding (CRIB) motif (GST-
PAK-PBD beads from Cytoskeleton, Denver, CO) as described in
[7,6]. Proteins were Western blotted using an anti-Rac antibody (Cell
Signaling Technology, Inc., Danvers,MA). Positive bands were imaged
using ChemiDoc MP system (Bio-Rad, Hercules, CA) and quantified
using Image J software. Rac activity was determined as the Rac-GTP
bound to the PAK–CRIB domain as a function of total Rac.
Apoptosis Assay
Apoptosis was measured by relative caspase 3/7 activity, as
described in [56], using a Caspase-Glo3/7 Luminescence Assay Kit
as per manufacturer’s instructions (Promega, Corp., Madison, WI,
USA). Following treatment of MDA-MB-435 cells with vehicle or
Ehop-016 at 5, 10, or 25 μM, 100 μl of Caspase-3/7 Glo reagent was
added and incubated at room temperature for 60 minutes. Caspase-
3/7 activities were determined by quantifying luminescence.
Western Blotting
MDA-MB-435 or PC3 cells were treated with vehicle, or 4 or 8 μM
Ehop-016 for 24 h. Cells were immediately lysed as in [57] and total
protein was quantified using the Precision Red protein assay kit
(Cytoskeleton, Inc., Denver, CO). Equal total protein amounts were
Western blotted using anti-Akt, anti-phospho AktThr308, anti-JNK,
anti-phospho JNKThr183/Try185, anti-c-Myc, or anti-Cyclin D (Cell
Signaling Technology, Inc., Danvers, MA) antibodies. The integrated
density of positive bands was quantified using Image J software.
Animals
All animal studies were conducted under approved protocol
#A8180112 by the University of Puerto Rico Medical Sciences
Campus Institutional Animal Care and Use Committee, in
accordance with the principles and procedures outlined in the NIH
Guideline for the Care and Use of Laboratory Animals.
Female athymic nu/nu mice, 4 to 5 weeks old (Charles River
Laboratories, Inc., Wilmington, MA) were maintained under
pathogen-free conditions in HEPA-filtered cages (5 mice per cage)under controlled light (12 h light and dark cycle), temperature (22 to
24°C), and humidity (25%). The animals received autoclaved rodent
diet (Tek Global, Harlan Teklad, Madison, WI) with 24.5% protein,
4.3% fat and 3.7% fiber and water ad libitum.
Tumor Establishment
GFP-MDA-MB-435 cells (~ 0.5 × 106) in Matrigel (BD
Biosciences, San Jose, CA) were injected at the fourth right mammary
fat pad under isofluorane inhalation (1% to 3% in oxygen using an
inhalation chamber at 2 L/min) to produce orthotopic primary
tumors as described in [57]. After tumor establishment (1 wk post-
inoculation), the animals from the same litter with similar weight and
tumor size were randomly divided into experimental treatment
groups. The study was initiated with 10 mice/group. However, due to
unforeseen mouse deaths (but not from EHop-016-mediated
toxicity), the numbers on the last day were: Vehicle, N = 6;
10 mg/kg BW, N = 8; and 25 mg/kg BW, N = 4.
Administration of EHop-016
Mice were treated with vehicle (12.5% ethanol (Sigma-Aldrich, St.
Louis, MO), 12.5% Cremophor (Sigma-Aldrich, St. Louis, MO),
and 75% 1× PBS pH 7.4), or 10 or 25 mg/kg BW Ehop-016 by
intraperitoneal (i.p.) injection in a 100 μl volume every other day, 3
times a week. Treatments continued until sacrifice at day 55.
Whole Body Fluorescence Image Analysis
Mammary tumor growth was quantified as changes in the
integrated density of GFP fluorescence, using methods developed
by Hoffman and co-workers [58]. Mice were imaged one week
following breast cancer cell inoculation (on day 1 of treatment
administration) and once a week thereafter. The FluorVivo small
animal In Vivo imaging system (INDEC Systems, Inc., Santa Clara,
CA) was used for whole body imaging of GFP fluorescence.
Tumor fluorescence intensities were analyzed using Image J software
(National Institutes of Health, Bethesda, MD). The final images were
acquired on day 55. Relative tumor growth was calculated as the
integrated density of fluorescence of each tumor on each day of imaging
relative to the integrated density of fluorescence of the same tumor on
day 1 of treatment administration, as described in [55,57].
Analysis of Metastases
Following sacrifice, lungs, kidneys, livers, and spleens were excised
and immediately stored in liquid N2. Stored organs were thawed and
analyzed using an Olympus MV10 fluorescence macro zoom system
microscope and images acquired with an Olympus DP71 digital
camera, as described in [57]. Each organ was imaged on both sides.
The fluorescent lesions (green component of RGB images) were
quantified for integrated density of fluorescent pixels using Image
J software.
Ehop-016 Detection by Ultra Performance Liquid Chromato-
graphy/Tandem Mass Spectrometry (UPLC-MS/MS)
Plasma Ehop-016 was quantified using an automated UPLC
system coupled to a triple quadrupole tandem mass spectrometer
(MS/MS) (Agilent Technologies, Santa Clara, CA). The data was
collected and analyzed by the Agilent MassHunter software package
(Version B.05.01). The UPLC separations were performed on a
Poroshell 120 EC-C18 column (50 mm × 3.0 mm) with 2.7 μm
particle size (Agilent, CA) under gradient conditions with a mobile
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and 50% Acetonitrile/50% methanol/0.1% formic acid solution
(solution B) at a flow rate of 0.5 ml/min at 40 °C. The initial mobile
phase composition was 65% of solution A and 35% of solution B.
The content of solution B was increased by a linear gradient to 98%
from 2.5 minutes to 3.0 minutes. After 4.5 minutes, the content of
solution B was decreased by a linear gradient to 35%. Finally, the
column was equilibrated at the initial conditions for 1.5 minutes. The
total run time for analysis was 6.5 minutes and the injection volume
was 1 μl.
Statistical Analysis
Data are expressed as the mean ± SEM. Statistical analyses were
done using Microsoft Excel and GraphPad Prism. Differences
between groups were considered to be statistically significant at P ≤
.05. Differences between means for vehicle were compared with
means for 10 mg/kg BW EHop-016 or 25 mg/kg BW Ehop-016
using Student’s t test. One-way ANOVAs were also performed for all
3 groups and the statistical significance determined by Kruskal–Wallis
test and Dunn’s multiple comparisons test.
Results and Discussion
Metastasis, the migration of cancer cells away from the primary tumor
to establish secondary tumors at distant sites, is a major cause of
failure in cancer therapy and patient survival. Thus, there is an urgent
need for strategies that specifically target migratory, and thus,
metastatic cancer cells [2]. The Rho GTPases Rac and Cdc42 have
been implicated in cancer progression via control of cancer cell
proliferation, survival, migration/invasion, and metastasis [2,59–61].
Therefore, we initiated the development of Rac and Cdc42 inhibitors
as potential anti metastatic cancer therapeutics, using the established
Rac inhibitor NSC23766 as a lead compound [51]. Recently, we
disclosed the development of EHop-016, which inhibits Rac activity
of metastatic cancer cells with an IC50 of 1 μM, and is the first
compound reported to inhibit the activation of Rac by the oncogenic
GEF Vav. EHop-016 inhibits the activity of the Rac downstream
effector PAK, lamellipodia extension, and cell migration of metastatic
cancer cells. At higher concentrations (≥10 μM) EHop-016 also
inhibits Cdc42 activity and cell viability [52]. Herein, our objective
was to test the feasibility of EHop-016 as a tool to inhibit metastatic
cancer progression, using an athymic nude mouse model of
experimental metastasis.
EHop-016 Reduces Mammary Tumor Growth
EHop-016 was administered by interperitoneal (i.p.) injection to
nudemice with mammary tumors established fromGFP-taggedMDA-
MB-435 human metastatic cancer cells. Tumor growth was quantified
as a measure of the fluorescence intensity of the primary mammary
tumor of each mouse relative to day 1 from fluorescence images
acquired once a week for 8 weeks. Administration of 25 mg/kg BW
EHop-016 three times a week for 8 weeks resulted in a ~80% reduction
in tumor growth compared to vehicle. As determined by Students t test,
the decrease in tumor growth at 25 mg/kg BW EHop-016 was
statistically significant when compared to vehicle or 10 mg/kg BW
EHop-016 for the final four weeks of the study (Figure 1, A and B). On
the final day of imaging, the comparison of tumor intensities between 0
and 10 mg/kg BW treatments with 25 mg/kg BW treatment was
statistically significant when compared by the Kruskall–Wallis test. The
Dunn’s multiple comparison test demonstrated statistical significancebetween 10 mg/kg BW treatment and the 25 mg/kg BW treatment,
but not between 0 and the 25 mg/kg BW treatment. On the other
hand, administration of 10 mg/kg BW EHop-016 did not cause
significant changes in tumor growth when compared to the vehicle
control (Figure 1B), as determined by the Students t test, as well as one-
way ANOVA, using Kruskal-Wallis and Dunn’s multiple comparisons
tests. These results demonstrate a concentration dependent effect of
Ehop-016 on tumor growth.
Figure 1C demonstrates that at 25 mg/kg BW, EHop-016 did not
cause significant weight changes in the nude mice. Moreover, these
animals did not demonstrate any gross phenotypical changes in skin
color and malleability, or behavior. Alanine transaminase activity
from liver lysates also demonstrated no change from vehicle controls
(data not shown). Therefore, EHop-016 does not appear to be toxic
to the animals at the effective concentration.
EHop-016 Levels in Mouse Plasma
To determine whether adequate EHop-016 levels were being
delivered to the tumor tissue, we quantified the EHop-016
concentration in mouse plasma from blood collected at the end of
the study. Mice were treated with EHop-016 three times a week for
55 days, with the final i.p. administration at 12 h prior to blood
collection from cardiac puncture. A method was developed using
UPLC-MS/MS to quantify EHop-016 from mouse plasma. EHop-
016 was detected at ~17 ng/ml or 23 ng/ml (0.0395 or 0.0534 μM)
in the mouse plasma, following 12 h administration of 4.65 mM
EHop-016 (10 mg/kg BW EHop-016) or 11.61 mM EHop-016
(25 mg/kg BW EHop-016), respectively, in 100 μl in a 20 g mouse
(Table 1). This low recovery rate in plasma may be due to a faster
clearing rate of EHop-016 from the blood via high tissue absorbance
of this highly lipophilic molecule. Alternatively, EHop-016 may
become metabolized or become unavailable for detection due to
sequestration by carrier proteins in the blood. These mechanisms of
drug elimination from the mouse plasma are currently being explored.
EHop-016 Inhibits Metastasis
The In Vivo study was terminated at 55 days, and the distant
organs were excised and quantified for fluorescent metastatic foci. As
shown in Figure 2 and Table 2, EHop-016 at 25 mg/kg BW
dramatically reduced metastasis to lung, liver, spleen, and kidneys.
A number of studies have implicated Rac in cancer metastasis
[15,62]. Therefore, our results (Figures 1 and 2 and Table 2) further
implicate Rac in the regulation of tumor growth and metastasis and
demonstrate the utility of Rac inhibition as a strategy to block cancer
progression. This study that demonstrates inhibition of metastasis, to
all distant organs examined following EHop-016 treatment, may
indicate that EHop-016 is inhibiting the intravasation step, when
cancer cells migrate away from the primary mammary tumor to enter
the circulation. Conversely, the marked reduction in tumor growth
by EHop-016 may reduce the number of cells that are shed from the
primary tumors and thus, effectively block metastasis. Future studies
testing the effect of EHop-016 in spontaneous metastasis assays are
expected to elucidate whether EHop-016 blocks the extravasation of
metastatic cancer cells to establish metastases at distant sites.
EHop-016 Inhibits Angiogenesis
Angiogenesis is essential to cancer progression, where the
endothelial cells in the tumor microenvironment form new blood
vessels to sustain the growing tumor. A pertinent observation from
Figure 1. Effect of EHop-016 on mammary fat pad tumor growth. Athymic nude mice were inoculated at the mammary fat pad with GFP-
MDA-MB-435 cells. Average relative tumor growth from fluorescence in situ images up to 55 days following 0, 10, or 25 mg/kg body weight
(BW) EHop-016 (three times a week) was determined. (A) Relative tumor growth as a function of days following EHop-016 administration.
(B) AverageRelative tumor intensity onday 55 (N=6,0 mg/kgBW;N=8,10 mg/kgBW;N=4,25 mg/kgBW).Error bars=SEM, *=pb 0.05.
(C) Average mouse weight as a function of days following EHop-016 administration.
Table 1. EHop-016 levels in mouse plasma. EHop-016 was detected at ng/ml quantities from
mouse plasma, using UPLC-MS/MS, following 10, or 25 mg/kg BW EHop-016 for 12 h. Data are
expressed as the Mean ± SEM
EHop-016 Administered (mg/kg BW) Ehop-016 in plasma (ng/ml)
10 17.1 ± 4.6
25 23.3 ± 6.5
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mammary tumors from mice treated with 25 mg/kg BW EHop-016,
compared to those treated with vehicle (Figure 3A). Therefore, tumor
tissue was subjected to immunofluorescence for CD31, an endothelial
cell marker. As expected, the tumors from mice that received vehicle
controls demonstrated tubes arranged as capillaries. However, the
tumors from mice that received EHop-016 demonstrated a ~85%
decrease in capillary formation, as quantified from fluorescence
micrographs (10 microscopic sections each for N = 2) of tissues stained
for CD-31 for 0 and 25 mg/kg BW EHop-016 treatments (Figure 3A).
The ability of EHop-016 to inhibit Rac activity and capillary tube
formation was also confirmed In Vitro using Human Umbilical Vein
Endothelial Cells (HUVECs). As expected, EHop-016 inhibited the
aggregation of endothelial cells into tubes. At 4 μMEHop-016, there
was reduced tube formation, which was impaired at 8 μM, theconcentration at which we observed a 50% reduction in Rac activity.
(Figure 3B). Since Racs [1,2] play an essential role in blood vessel
morphogenesis via integrin signaling and endothelial cell prolifera-
tion/adhesion/migration mechanisms [63–65], we expect EHop-016
to additionally block tumor growth by reducing their blood supply via
inhibition of the Rac activity of endothelial cells.
In this study, for the first time, we have shown that EHop-016 can
be used effectively to block mammary tumor progression to
metastasis. This anticancer activity of EHop-016 is predicted to be
due to inhibition of Rac, and possibly Cdc42, activities in the human
breast cancer cells as well as the endothelial cells in the tumor
microenvironment. Therefore, EHop-016 may inhibit mammary
tumor growth via multiple mechanisms of blocking the growth and
migration of tumor cells and endothelial cells. Future studies will
investigate the effect of EHop-016 on additional cells in the tumor
microenvironment, such as macrophages and neutrophils as well as T
and B lymphocytes that are regulated by Vav1/Rac2 signaling [66].
Recent studies have documented the utility of inhibiting Rac and
Cdc42 to reduce tumor growth and metastasis in xenograft models.
Another NSC23766 analog AZA1 (at 100 μg/day) was shown to
inhibit Rac1 and Cdc42 in prostate cancer cells and reduce tumor
growth via inhibition of Rac/Cdc42/PAK signaling to the actin
cytoskeleton as well as Akt and Cyclin D to reduce cell survival and
Figure 2. Effect of EHop-016 on metastasis. Mammary fat pad tumors were established in athymic nude mice using GFP-MDA-MB-435
cells. Mice were treated with 0, 10, or 25 mg/kg body weight (BW) EHop-016 (three times a week) (N = 5). Lungs, livers, kidneys, and
spleens were removed at necropsy and imaged for fluorescent metastatic foci. (A) Representative organs under fluorescencemicroscopy
for 25 mg/kg BWEhop-016 treatment. (B) Average integrated intensity of fluorescentmetastatic foci/organ. Error bars=SEM, *=p b 0.05.
Table 2. Average integrated density (1 × 103) of metastatic foci
Organ Lung Spleen Liver Kidney
Treatment
Veh 61.4 157.4 97.6 7.4
Ehop-016 (25 mg/kg BW) 0.73 0 5.2 0
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25 mg/kg BW, and its analog IA-116 at 3 mg/kg BW, resulted in
reduced lung metastases from spontaneous metastases assays [47].
Similarly a Cdc42 specific inhibitor, AZA197, suppressed colon
cancer growth via down-regulation of PAK and ERK activities, and
Cyclin D1 expression [48]. Therefore, we expect EHop-016 to
inhibit mammary tumor progression via multiple Rac/Cdc42/PAK-
mediated signaling mechanisms.
EHop-016 Inhibits Rac/Cdc42/PAK-Mediated Cell Survival/
Proliferation Signaling
To understand the mechanism by which EHop-016 reduces tumor
growth, we investigated the effect of EHop-016 on apoptosis and cell
survival signaling In Vitro. As previously shown by us, at
concentrations ≥10 μM EHop-016 inhibits Rac and PAK activities
by ~100% and Cdc42 activity by 75%, and reduces cell viability [52].
Figure 4 shows that in MDA-MB-435 metastatic cancer cells, at
concentrations ≥10 μM, EHop-016 increases caspase 3/7 activity ina statistically significant (P b .05) and concentration-dependent
manner with a maximum 1.6-fold induction at 25 μM, at
concentrations that inhibit both Rac and Cdc42. This result indicates
that EHop-016 may induce mitochondrial and death receptor-
regulated apoptosis, and is consistent with a number of studies from
various cancer types that have implicated a role for Rac/Cdc42/PAK
signaling in cell survival and evasion of apoptosis [46,53,62].
Our previous studies demonstrated that EHop-016, at concentrations
b10 μM, inhibits the Rac activity of metastatic breast cancer cellsMDA-
MB-435 and MDA-MB-231 [52], as well as the SKBR3 cell line (data
not shown). To determine the potential of EHop-016 as a general Rac
inhibitor, we also tested the effect of EHop-016 in themetastatic prostate
cancer cell line PC3; a cell line that has been shown to be dependent on
Rac/Vav signaling for migration/invasion [67]. Figure 5A demonstrates
that 8 μM EHop-016 inhibits the Rac activity of PC3 cells by 50%.
To understand the mechanisms by which EHop-016 may reduce
cell survival and induce apoptosis, we investigated the effect of EHop-
016 on known Rac/Cdc42/PAK signaling pathway molecules, which
have been implicated in controlling cell survival and proliferation.
Activated Rac and Cdc42 may affect cell cycle progression via up-
regulation of the oncogenes Cyclin D and c-Myc [10,19,68,68–70].
Rac/PAK signaling also regulates cell growth via signaling to Akt,
ERK, JNK, and p38 MAPK [16,71]. Figures 4 and 5 show that in
both MDA-MB-435 and PC3 cells, EHop-016 significantly reduced
the expression of the oncogenic cell cycle regulators c-Myc and Cyclin
D expression by ~25% to 60%.
Figure 3. Effect of EHop-016 on angiogenesis. (A) Representative tumors from athymic nude mice inoculated at the mammary fat pad with
GFP-MDA-MB-435 cells and treatedwith 0 or 25 mg/kg bodyweight (BW) EHop-016 (three times aweek) (N=5). Left, stereoscopic images of
representative mammary tumors with blood vessels in red. Right, immunofluorescence micrographs of tissue sections with blood vessels
stained for DAPI or CD31 (red fluorescence). (B) Representativemicrographs following a tube formation assay usingHUVEC cells treatedwith
vehicle or 4or 8 μMEHop-016 for24 h (N=4). Arrows indicate capillaries (tubes). (C)RepresentativeWesternblot andquantificationof theRac
activity of HUVEC cells treated with 0 or 8 μMEHop-016 for 24 h from a pulldown assay for Rac.GTP (N = 2). Error bars = SEM, * = P b 0.05.
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and expression. EHop-016 did not affect ERK activity or expression
(data not shown). However, EHop-016 significantly reduced the
JNK activity of MDA-MB-435 cells by ~30%. In PC3 prostate
cancer cells, p-JNK levels were decreased but total JNK levels were
also reduced to a similar extent, indicating that JNK expression is also
down-regulated in this cell line. Moreover, in the MDA-MB-435
cells, EHop-016 reduced Akt activity by 40% at 4 and 8 μM,
without affecting the Akt activity of PC3 cells (data not shown).
These differences may be attributed to disparate cancer types of the
two different cell lines. Studies have also linked Akt activity and thus,
the regulation of the anti-apoptotic protein BAD with Rac action
[72], and may account of the observed reduction in caspase activity inthe MDA-MB-435 cell line, where a parallel 1.4-fold calculated
increase in caspase activity is observed at 8 μM, when Akt activity is
decreased by −1.4-fold (Figure 4, A and B). Therefore, EHop-016
may reduce cell viability and tumor growth via a number of Rac-
regulated pathways that control cell survival and death.
Conclusions
We have demonstrated that EHop-016 is a viable tool for blocking
Rac activity via inhibition of the Vav/Rac interaction and thus,
metastatic breast cancer cell migration In Vitro at μM concentrations
[52]. Following this publication, the utility of EHop-016 as a Rac
inhibitor has also been demonstrated in leukemia and melanoma cells
[50,53]. In this study, for the first time, we tested the efficacy of
Figure 4. Effect of EHop-016 on apoptosis and Rac/Cdc42/PAK signaling in MDA-MB-435 cells. A) Fold change in caspase 3/7 activity in
response to EHop-016. MDA-MB-435 cells treated for 24 h with 0, 5, 10, or 25 μMEHop-016 and subjected to caspase 3/7 activity assays.
N = 3 ± SEM, Asterisk = P b .05. B-D. MDA-MB-435 cells treated with 0, 4, or 8 μM EHop-016 were lysed, and equal amounts of protein
subjected to Western blotting followed by integrated density of positive bands. N = 2 to 5 ± SEM; Asterisk = P b .05. (B) Representative
Western blot stained for c-Myc or Cyclin D and quantification of relative protein expression. (C) Representative Western blot stained for
phospho (p)-Akt, Akt, p-JNK, or JNK. (D) Quantification of relative protein phosphorylation.
Translational Oncology Vol. 7, No. 5, 2014 EHop-016 Inhibits Tumor Progression Castillo-Pichardo et al. 553EHop-016 In Vivo. Our results, using a nude mouse model of
experimental metastasis, demonstrate that EHop-016 significantly
reduces mammary fat pad tumor growth and metastasis, as well as
angiogenesis. The In Vitro assays with HUVEC cells, MDA-MB-435
cells, and PC3 cells further validate the use of EHop-016 to inhibit
Rac, and thus, reduce cancer cell survival and proliferation, and
inhibit metastatic cancer progression. Therefore, our data is
significant for demonstrating the utility of developing chemical
probes targeted at Rac, and the homolog Cdc42, as potential anti
cancer therapeutics.
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